These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24647711)

  • 21. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease.
    Wu M; Wahl PR; Le Hir M; Wackerle-Men Y; Wuthrich RP; Serra AL
    Kidney Blood Press Res; 2007; 30(4):253-9. PubMed ID: 17596700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models.
    Chaudhary A; He Z; Atwood DJ; Miyazaki M; Oto OA; Davidoff A; Edelstein CL
    Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1004-F1015. PubMed ID: 38634129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats.
    Torres VE; Sweeney WE; Wang X; Qian Q; Harris PC; Frost P; Avner ED
    Kidney Int; 2004 Nov; 66(5):1766-73. PubMed ID: 15496147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of paclitaxel on the progression of polycystic kidney disease in rodents.
    Martinez JR; Cowley BD; Gattone VH; Nagao S; Yamaguchi T; Kaneta S; Takahashi H; Grantham JJ
    Am J Kidney Dis; 1997 Mar; 29(3):435-44. PubMed ID: 9041221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.
    Kipp KR; Kruger SL; Schimmel MF; Parker N; Shillingford JM; Leamon CP; Weimbs T
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F395-F405. PubMed ID: 29717938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease.
    Berthier CC; Wahl PR; Le Hir M; Marti HP; Wagner U; Rehrauer H; Wüthrich RP; Serra AL
    Nephrol Dial Transplant; 2008 Mar; 23(3):880-9. PubMed ID: 18042615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2-Hydroxyestradiol slows progression of experimental polycystic kidney disease.
    Anderson S; Oyama TT; Lindsley JN; Schutzer WE; Beard DR; Gattone VH; Komers R
    Am J Physiol Renal Physiol; 2012 Mar; 302(5):F636-45. PubMed ID: 22160773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of a modified low protein and low fat diet on histologic changes and metabolism in kidneys in an experimental model of polycystic kidney disease].
    Banković-Calić N; Ogbori MR; Nicman E
    Srp Arh Celok Lek; 2002; 130(7-8):251-7. PubMed ID: 12585002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).
    Zafar I; Belibi FA; He Z; Edelstein CL
    Nephrol Dial Transplant; 2009 Aug; 24(8):2349-53. PubMed ID: 19321761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease.
    Togawa H; Nakanishi K; Mukaiyama H; Hama T; Shima Y; Sako M; Miyajima M; Nozu K; Nishii K; Nagao S; Takahashi H; Iijima K; Yoshikawa N
    Am J Physiol Renal Physiol; 2011 Feb; 300(2):F511-20. PubMed ID: 21084407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Folate-conjugated rapamycin slows progression of polycystic kidney disease.
    Shillingford JM; Leamon CP; Vlahov IR; Weimbs T
    J Am Soc Nephrol; 2012 Oct; 23(10):1674-81. PubMed ID: 22859856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease.
    Kipp KR; Rezaei M; Lin L; Dewey EC; Weimbs T
    Am J Physiol Renal Physiol; 2016 Apr; 310(8):F726-F731. PubMed ID: 26764208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of vasopressin antagonists.
    Torres VE
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1212-8. PubMed ID: 18434616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic advances in the treatment of polycystic kidney disease.
    Riella C; Czarnecki PG; Steinman TI
    Nephron Clin Pract; 2014; 128(3-4):297-302. PubMed ID: 25573484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of intrahepatic bile duct dilation of the polycystic kidney rat with a novel tyrosine kinase inhibitor gefitinib.
    Sato Y; Harada K; Furubo S; Kizawa K; Sanzen T; Yasoshima M; Ozaki S; Isse K; Sasaki M; Nakanuma Y
    Am J Pathol; 2006 Oct; 169(4):1238-50. PubMed ID: 17003482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.
    Krämer S; Wang-Rosenke Y; Scholl V; Binder E; Loof T; Khadzhynov D; Kawachi H; Shimizu F; Diekmann F; Budde K; Neumayer HH; Peters H
    Am J Physiol Renal Physiol; 2008 Feb; 294(2):F440-9. PubMed ID: 18094032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapamycin-encapsulated nanoparticle delivery in polycystic kidney disease mice.
    Yamaguchi S; Sedaka R; Kapadia C; Huang J; Hsu JS; Berryhill TF; Wilson L; Barnes S; Lovelady C; Oduk Y; Williams RM; Jaimes EA; Heller DA; Saigusa T
    Sci Rep; 2024 Jul; 14(1):15140. PubMed ID: 38956234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat.
    Nagao S; Nishii K; Yoshihara D; Kurahashi H; Nagaoka K; Yamashita T; Takahashi H; Yamaguchi T; Calvet JP; Wallace DP
    Kidney Int; 2008 Feb; 73(3):269-77. PubMed ID: 17943077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydrochlorothiazide ameliorates polyuria caused by tolvaptan treatment of polycystic kidney disease in PCK rats.
    Wang A; Hirose T; Ohsaki Y; Takahashi C; Sato E; Oba-Yabana I; Kinugasa S; Muroya Y; Ito S; Mori T
    Clin Exp Nephrol; 2019 Apr; 23(4):455-464. PubMed ID: 30426292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.
    Dai B; Liu Y; Mei C; Fu L; Xiong X; Zhang Y; Shen X; Hua Z
    Clin Sci (Lond); 2010 Jul; 119(8):323-33. PubMed ID: 20507283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.